Reduction of the hepatic radioactivity levels of [ 111 In]In-DOTA-labeled antibodies via cleavage of a linkage metabolized in lysosomes.

A molecular design that reduces the high and persistent hepatic radioactivity of radiolabeled antibodies by liberating radiometabolites with a short hepatic residence time in lysosomes would be applicable for radiometal-labeled antibodies using a DOTA-chelating system.